EUVIMEDEUVIMED entdecken
Leitlinie

Development of new antithrombotic drugs for children (part 1): guidance from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis and the Pedi-ATLAS Group

Neil A Goldenberg, Scott D Berkowitz, Marisol Betensky, Susanne Holzhauer, Vera Ignjatovic, Amy Kiskaddon, Daniel Schaufelberger, Paul Monagle, Christoph Male, Antithrombotic Trials Working Party of ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis & Hemostasis, Pediatric Antithrombotic Trials Leadership and Steering (Pedi-ATLAS) Group

Journal of Thrombosis and Haemostasis · 2026

DOI: 10.1016/j.jtha.2026.04.003 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026. Verfasst von Neil A Goldenberg und 10 weiteren Autor:innen. Beteiligte Einrichtung: Johns Hopkins All Children's Institute for Clinical and Translational Research, St. Petersburg, Florida, USA; Department of Pediatrics, Johns Hopkins…. Hauptthemen laut MEDLINE: Anticoagulants, Drug Development, Fibrinolytic Agents, Hemostasis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As adult programs of newer anthrombotic agents, such as those directed against FXIa, are underway, there is both a pressing need and a great opportunity to optimize the design, conduct, and analysis of future pediatric trials. Recommendations for the development of new anticoagulation drugs for pediatric use were last published in 2015 on behalf of the ISTH SSC. The objective of the present manuscript is to provide updated guidance recommendations for the development of new antithrombotic drugs in children. Key recommendations include: 1) initiating pediatric pharmaceutical development (including oral formulation development) well before the intended start of pediatric clinical studies; 2) engaging multidisciplinary experts in pediatric thrombosis clinical care, clinical trials, and translational science; 3) employing extrapolation where appropriate, to assure that patient sample sizes in pediatric trials are no larger than necessary; 4) using modeling approaches to minimize patient sample sizes and optimize timing and frequency of blood sampling in pediatric PK/PD studies; 5) augmenting preclinical data from animal models (or non-animal approaches) with in vitro spiking studies using biospecimens obtained from relevant human pediatric populations; 6) addressing residual uncertainty in dose-finding, PK or PD from early-phase trials in the design of late-phase trials; and 7) committing to make all pediatric formulations found to be safe and efficacious in late-phase trials commercially available in all countries in which the trials are conducted. Additional guidance recommendations will be provided in a subsequent manuscript.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticoagulantsDrug DevelopmentFibrinolytic AgentsHemostasisThrombosisAnimalsChildChild, PreschoolHumansInfantInfant, NewbornAge FactorsBlood CoagulationClinical Trials as Topic

Stichwörter der Autor:innen

antithromboticchildrenclinical trialspediatricstrokethromboembolism

Substanzen

AnticoagulantsFibrinolytic Agents

Autor:innen und Institutionen

  • Johns Hopkins All Children's Institute for Clinical and Translational Research, St. Petersburg, Florida, USA; Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Department o…
  • CPC Clinical Research and Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
  • Johns Hopkins All Children's Institute for Clinical and Translational Research, St. Petersburg, Florida, USA; Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of Paediatric Haematology and Oncology, Paediatric Haemostasis Centre, Charité University Medicine, Berlin, Germany.
  • Johns Hopkins All Children's Institute for Clinical and Translational Research, St. Petersburg, Florida, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of Clinical Haematology, The Royal Children's Hospital, Parkville, Victoria, Australia.

Zitieren

APA

Goldenberg, N. A., Berkowitz, S. D., Betensky, M., Holzhauer, S., Ignjatovic, V., Kiskaddon, A., Schaufelberger, D., Monagle, P., Male, C., Antithrombotic Trials Working Party of ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis & Hemostasis, & Pediatric Antithrombotic Trials Leadership and Steering (Pedi-ATLAS) Group (2026). Development of new antithrombotic drugs for children (part 1): guidance from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis and the Pedi-ATLAS Group. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2026.04.003

Vancouver

Goldenberg NA, Berkowitz SD, Betensky M, Holzhauer S, Ignjatovic V, Kiskaddon A, et al. Development of new antithrombotic drugs for children (part 1): guidance from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis and the Pedi-ATLAS Group. Journal of Thrombosis and Haemostasis. 2026. doi:10.1016/j.jtha.2026.04.003

BibTeX
@article{Goldenberg2026,
  author = {Goldenberg, Neil A and Berkowitz, Scott D and Betensky, Marisol and Holzhauer, Susanne and Ignjatovic, Vera and Kiskaddon, Amy and Schaufelberger, Daniel and Monagle, Paul and Male, Christoph and Antithrombotic Trials Working Party of ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis & Hemostasis, Antithrombotic Trials Working Party of ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis & Hemostasis and Pediatric Antithrombotic Trials Leadership and Steering (Pedi-ATLAS) Group, Pediatric Antithrombotic Trials Leadership and Steering (Pedi-ATLAS) Group},
  title = {Development of new antithrombotic drugs for children (part 1): guidance from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis and the Pedi-ATLAS Group},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2026},
  doi = {10.1016/j.jtha.2026.04.003}
}
Kostenlos starten →